Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
DiscussionThis is the first randomised control trial to study the efficacy of rituximab as first-line treatment in CTD-associated ILD. The results generated should provide important information on the treatment of a life-threatening complication affecting a rare group of CTDs.Trial registrationClinicalTrials.gov, NCT01862926. Registered on 22 May 2013. (Source: Trials)
Source: Trials - June 15, 2017 Category: Research Source Type: clinical trials
Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis
Condition: Treatment Side Effects Intervention: Drug: Lipid-lowering agents (Artovastatin) Sponsor: University of Sao Paulo Recruiting - verified March 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 9, 2017 Category: Research Source Type: clinical trials
Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Polymyositis; Dermatomyositis Interventions: Drug: Abatacept; Drug: Placebo Sponsor: Bristol-Myers Squibb Not yet recruiting - verified November 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2016 Category: Research Source Type: clinical trials
